Japan's Ajinomoto Bio-Pharma Services takes control of GeneDesign

Japan's Ajinomoto Bio-Pharma Services' GeneDesign has expanded it production capabilities for oligonucleotides, the short DNA or RNA molecules oligomers used in gene therapies. (GeneDesign)

Ajinomoto Bio-Pharma Services has concluded a process that will allow the CDMO to operate in the gene therapy space. The company has fully integrated oligonucleotides producer GeneDesign into its operations.

GeneDesign was acquired by Ajinomoto Co. in 2017 but now will be under the control of its small- and large-molecule API producer, Ajinomoto Bio-Pharma Services. The deal comes as GeneDesign has completed a 2,000-square-meter facility that allows it to expand its synthesis and supply of the DNA and RNA molecules up to 10 kg.

RELATED: Ajinomoto Althea expanding GMP production at California facility

“The integration of GeneDesign into Aji Bio-Pharma allows us to more seamlessly support our biopharmaceutical customers globally with a wide range of service offerings in one consolidated supply chain,” Ajinomoto Bio-Pharma Services CEO David Enloe said in a statement.

Gene Design’s new facility at its Osaka campus has space for manufacturing oligonucleotide APIs as well as to custom synthesize heavily modified oligonucleotides, it said. It also has development labs to support manufacturing activities and R&D labs for the development of novel oligonucleotide manufacturing technologies.

The CDMO already produces both small- and large-molecule APIs and intermediates at its sites in Japan, Belgium, India and the U.S. In 2017, it expanded its GMP production at its high-potency products manufacturing facility in San Diego. The CDMO last month said it will spend about $100 million to further expand capabilities at the U.S. site, as well as its site in Belgium.  

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.